×
ADVERTISEMENT

MARCH 23, 2022

FDA Approves Breyna, First Generic of Symbicort to Treat Asthma and COPD

By PPN News Staff

The FDA approved the first generic of Symbicort (AstraZeneca), budesonide and formoterol fumarate dihydrate (Breyna, Viatris/Kindeva), an inhaled medication used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).

Breyna is approved for asthma patients who are 6 years of age and older. This complex generic drug–device combination product, which is a metered-dose inhaler, should not be used to treat acute asthma attacks, the FDA said.